JP2020090508A5 - - Google Patents

Download PDF

Info

Publication number
JP2020090508A5
JP2020090508A5 JP2020003665A JP2020003665A JP2020090508A5 JP 2020090508 A5 JP2020090508 A5 JP 2020090508A5 JP 2020003665 A JP2020003665 A JP 2020003665A JP 2020003665 A JP2020003665 A JP 2020003665A JP 2020090508 A5 JP2020090508 A5 JP 2020090508A5
Authority
JP
Japan
Prior art keywords
acid
pharmaceutical composition
dgla
composition according
atopic dermatitis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2020003665A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020090508A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2020090508A publication Critical patent/JP2020090508A/ja
Publication of JP2020090508A5 publication Critical patent/JP2020090508A5/ja
Priority to JP2022030554A priority Critical patent/JP2022071061A/ja
Withdrawn legal-status Critical Current

Links

JP2020003665A 2014-06-04 2020-01-14 Ｄｇｌａを含む薬学的組成物及びその使用 Withdrawn JP2020090508A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022030554A JP2022071061A (ja) 2014-06-04 2022-03-01 Ｄｇｌａを含む薬学的組成物及びその使用

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462007752P 2014-06-04 2014-06-04
US62/007,752 2014-06-04
US201462058469P 2014-10-01 2014-10-01
US62/058,469 2014-10-01

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2016570986A Division JP2017516823A (ja) 2014-06-04 2015-06-04 Ｄｇｌａを含む薬学的組成物及びその使用

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022030554A Division JP2022071061A (ja) 2014-06-04 2022-03-01 Ｄｇｌａを含む薬学的組成物及びその使用

Publications (2)

Publication Number Publication Date
JP2020090508A JP2020090508A (ja) 2020-06-11
JP2020090508A5 true JP2020090508A5 (enExample) 2020-07-30

Family

ID=53298373

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2016570986A Pending JP2017516823A (ja) 2014-06-04 2015-06-04 Ｄｇｌａを含む薬学的組成物及びその使用
JP2020003665A Withdrawn JP2020090508A (ja) 2014-06-04 2020-01-14 Ｄｇｌａを含む薬学的組成物及びその使用
JP2022030554A Pending JP2022071061A (ja) 2014-06-04 2022-03-01 Ｄｇｌａを含む薬学的組成物及びその使用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2016570986A Pending JP2017516823A (ja) 2014-06-04 2015-06-04 Ｄｇｌａを含む薬学的組成物及びその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022030554A Pending JP2022071061A (ja) 2014-06-04 2022-03-01 Ｄｇｌａを含む薬学的組成物及びその使用

Country Status (17)

Country Link
US (9) US9682055B2 (enExample)
EP (2) EP3692986A1 (enExample)
JP (3) JP2017516823A (enExample)
KR (1) KR102391827B1 (enExample)
CN (1) CN107072959A (enExample)
AU (2) AU2015270418B2 (enExample)
BR (1) BR112016028518A2 (enExample)
CA (1) CA2953633A1 (enExample)
ES (1) ES2784240T3 (enExample)
IL (2) IL249364B (enExample)
MA (1) MA52644A (enExample)
MX (2) MX375328B (enExample)
PH (1) PH12016502530A1 (enExample)
RU (2) RU2020101477A (enExample)
SG (2) SG10201912145VA (enExample)
WO (1) WO2015185698A1 (enExample)
ZA (2) ZA201708681B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0907413D0 (en) 2009-04-29 2009-06-10 Equateq Ltd Novel methods
ES2727387T3 (es) 2013-11-15 2019-10-15 Ds Biopharma Ltd Sal de lisina de ácido 15-hidroxi-8(Z),11(Z),13(E)-eicosatrienoico
MX375328B (es) 2014-06-04 2025-03-06 Ds Biopharma Ltd Composiciones farmacéuticas que comprenden ácido dihomo-gamma-linolénico (dgla) y uso de las mismas
US10047033B2 (en) 2015-05-13 2018-08-14 Ds Biopharma Limited Compositions comprising oxo-derivatives of fatty acids and methods of making and using same
CN108778266A (zh) * 2016-01-07 2018-11-09 Ds生物制药有限公司 包含二高γ亚麻酸（DGLA）的医药组合物和其用途
EP3624787A1 (en) * 2017-05-19 2020-03-25 DS Biopharma Limited Pharmaceutical compositions comprising dgla and use of same
JP7500037B2 (ja) * 2019-07-24 2024-06-17 国立大学法人 東京大学 血中尿酸値低下剤及び血中尿酸値低下用食品組成物
US20210315851A1 (en) 2020-04-03 2021-10-14 Afimmune Limited Compositions comprising 15-hepe and methods of treating or preventing hematologic disorders, and/or related diseases

Family Cites Families (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5264452A (en) 1975-11-18 1977-05-27 Nippon Suisan Kaisha Ltd Method of producing processed fish meat
JPS5820575B2 (ja) 1975-11-27 1983-04-23 日本水産株式会社 スイサンカコウヒンノセイゾウホウ
US4273763A (en) 1978-01-23 1981-06-16 Efamol Limited Pharmaceutical and dietary compositions
IE47777B1 (en) * 1978-01-23 1984-06-13 Efamol Ltd Pharmaceutical and dietary composition comprising gamma-linolenic acids
US4444755A (en) 1978-01-23 1984-04-24 Efamol Limited Treatment for skin disorders
EP0004770B1 (en) * 1978-04-11 1984-06-13 Efamol Limited Pharmaceutical and dietary composition comprising gamma-linolenic acids
IE49783B1 (en) 1979-05-18 1985-12-11 Efamol Ltd Pharmaceutical and dietary composition comprising epsilon-linolenic acids
IE51145B1 (en) 1980-03-07 1986-10-15 Efamol Ltd Pharmaceutical and dietary compositions
IE53332B1 (en) 1980-03-14 1988-10-26 Efamol Ltd Pharmaceutical compositions
US5324748A (en) 1981-07-14 1994-06-28 Efamol Limited Method for enhancement of 1-series PG production
EP0087865B1 (en) 1982-03-01 1986-10-01 Efamol Limited Pharmaceutical composition
DE3363567D1 (en) 1982-03-01 1986-06-26 Efamol Ltd Pharmaceutical and dietary composition
ATE22804T1 (de) 1982-03-01 1986-11-15 Efamol Ltd Pharmazeutische zusammensetzung.
IE54795B1 (en) 1982-04-29 1990-02-14 Efamol Ltd Pharmaceutical composition
GB8302708D0 (en) * 1983-02-01 1983-03-02 Efamol Ltd Pharmaceutical and dietary composition
GB8319073D0 (en) 1983-07-14 1983-08-17 Efamol Ltd Fatty acid compositions
GB8326130D0 (en) 1983-09-29 1983-11-02 Efamol Ltd Topical preparations containing tars and fatty acids
GB8420771D0 (en) 1984-08-15 1984-09-19 Efamol Ltd Treatment of skin disorders
GB8425006D0 (en) 1984-10-03 1984-11-07 Efamol Ltd Composition of copper/fatty acids
GB8506027D0 (en) 1985-03-08 1985-04-11 Efamol Ltd Pharmaceutical & dietary compositions
GB8522670D0 (en) 1985-09-13 1985-10-16 Efamol Ltd Drug treatments
GB8524275D0 (en) 1985-10-02 1985-11-06 Efamol Ltd Pharmaceutical & dietary compositions
US5198468A (en) 1987-06-24 1993-03-30 Efamol Holdings Plc Essential fatty acid composition
EP0309086A1 (en) 1987-09-07 1989-03-29 Efamol Holdings Plc Treatment of male pattern baldness and of unwanted hair growth
GB8729153D0 (en) 1987-12-14 1988-01-27 Efamol Ltd Fatty acid compositions
WO1990014824A1 (en) 1988-01-14 1990-12-13 Anders Frithz Use of essential fatty acids for the preparation of a drug for the treatment of eczema
GB8806737D0 (en) 1988-03-22 1988-04-20 Efamol Holdings Therapeutic composition & method
US6140304A (en) 1988-09-28 2000-10-31 Eicotech Corporation Method of and nutritional and pharmaceutical compositions for reduction of hyperinsulinemia
CA1334002C (en) 1988-09-28 1995-01-17 Barry D. Sears Essential fatty acid compositions and methods for the modulation of prostaglandin levels in mammals
GB8916734D0 (en) * 1989-07-21 1989-09-06 Efamol Holdings Pharmaceutical and dietary uses of fatty acids
GB8918294D0 (en) 1989-08-10 1989-09-20 Efamol Holdings Pharmaceutical compositions
GB8920228D0 (en) 1989-09-07 1989-10-18 Efamol Holdings Fatty acid therapy
JPH04290820A (ja) 1991-03-18 1992-10-15 Idemitsu Petrochem Co Ltd 皮膚病犬の治療方法とその薬剤
GB9111900D0 (en) * 1991-06-03 1991-07-24 Efamol Holdings Fatty acid compositions
GB9112052D0 (en) 1991-06-05 1991-07-24 Efamol Holdings Fatty acid treatment
JP3354581B2 (ja) 1991-09-30 2002-12-09 サントリー株式会社 ジホモ−γ−リノレン酸及びこれを含有する脂質の製造方法
GB9211229D0 (en) 1992-05-27 1992-07-08 Efamol Holdings Fatty acid treatment
GB9217780D0 (en) 1992-08-21 1992-10-07 Efamol Holdings Fatty acid treatment
US5888541A (en) 1992-08-21 1999-03-30 Scotia Holdings Plc Fatty acid treatment
FI101039B (fi) 1992-10-09 1998-04-15 Eeva Kristoffersson Menetelmä lääkepellettien valmistamiseksi
DE4238869C2 (de) 1992-11-18 1994-09-08 Wogepharm Gmbh Mittel zur Behandlung des atopischen Ekzems und anderer entzündlicher Hautkrankheiten
GB9301446D0 (en) * 1993-01-26 1993-03-17 Scotia Holdings Plc Internal radiation damage
AU673700B2 (en) * 1993-01-27 1996-11-21 Scotia Holdings Plc Triglycerides
CA2119000A1 (en) 1993-03-19 1994-09-20 David Frederick Horrobin Formulation for use in smokers
DE69407949T2 (de) * 1993-10-01 1998-05-14 Scherer Corp R P Zusammensetzungen zum verteilen von duftstoffen
GB9403855D0 (en) * 1994-03-01 1994-04-20 Scotia Holdings Plc Fatty acid derivatives
US5789441A (en) 1996-02-15 1998-08-04 Virocell Inc. Leukotriene B4 as an antiviral and anti-neoplastic agent
GB9621373D0 (en) 1996-10-14 1996-12-04 Scotia Holdings Plc Fatty acid treatment
GB9710351D0 (en) 1997-05-20 1997-07-16 Scotia Holdings Plc Glucosamine fatty acids
GB9715444D0 (en) * 1997-07-22 1997-09-24 Scotia Holdings Plc Therapeutic and dietary compositions
JP2000191525A (ja) 1998-12-25 2000-07-11 Nof Corp 皮膚外用剤組成物
GB9916536D0 (en) 1999-07-14 1999-09-15 Scarista Limited Nutritional or pharmaceutical compositions
PT1072198E (pt) 1999-07-28 2008-06-17 Swiss Caps Rechte & Lizenzen Preparado, especialmente para utilização como medicamento e/ou como suplemento alimentar
IL151299A0 (en) 2000-02-16 2003-04-10 Brigham & Womens Hospital Aspirin-triggered lipid mediators
GB0016045D0 (en) 2000-06-29 2000-08-23 Laxdale Limited Therapeutic combinations of fatty acids
JP2002047176A (ja) * 2000-08-04 2002-02-12 Idemitsu Technofine Co Ltd ＩｇＥ産生抑制剤
US20020188024A1 (en) 2000-08-23 2002-12-12 Chilton Floyd H. Fatty acid-containing emulsion with increased bioavailability
US20040043013A1 (en) 2000-12-28 2004-03-04 Mccleary Edward Larry Metabolic uncoupling therapy
DE10121252A1 (de) 2001-04-30 2002-11-07 Christos C Zouboulis Behandlung der Akne
US20020198177A1 (en) 2001-05-30 2002-12-26 Horrobin David Frederick Coenzyme Q and EPA
JP2003155233A (ja) 2001-11-16 2003-05-27 Idemitsu Technofine Co Ltd 塗布剤
US20040122105A1 (en) 2002-09-20 2004-06-24 Griscom Bettle Transdermal compositions
JPWO2004048497A1 (ja) 2002-11-22 2006-03-30 日本水産株式会社 高度不飽和脂肪酸、その塩、またはそのエステルを含有する外用組成物
US20050032757A1 (en) * 2003-08-06 2005-02-10 Cho Suk H. Nutritional supplements
JP2005179211A (ja) 2003-12-17 2005-07-07 Idemitsu Kosan Co Ltd 皮膚外用剤組成物
WO2005063231A2 (en) 2003-12-31 2005-07-14 Igennus Limited Formulation containing an eicosapentaenoic acid or an ester thereof and a triterpene or esther thereof
AU2005262392A1 (en) 2004-07-01 2006-01-19 Johnson & Johnson Vision Care, Inc. Compositions and methods for treating eye disorders and conditions
US7666447B2 (en) * 2004-10-08 2010-02-23 Pharmanutrients Compositions including Krill extracts and conjugated linoleic acid and methods of using same
US7893106B2 (en) 2004-11-19 2011-02-22 Martek Biosciences, Corporation Oxylipins from stearidonic acid and γ-linolenic acid and methods of making and using the same
JP5546087B2 (ja) 2005-02-14 2014-07-09 サントリーホールディングス株式会社 皮膚疾患経口治療または予防剤
CA2599112C (en) 2005-02-14 2013-10-22 Suntory Limited Composition comprising dihomo-.gamma.-linolenic acid (dgla) as the active ingredient
JP2006306812A (ja) 2005-04-28 2006-11-09 Suntory Ltd 好酸球浸潤抑制剤
US7485323B2 (en) 2005-05-31 2009-02-03 Gelita Ag Process for making a low molecular weight gelatine hydrolysate and gelatine hydrolysate compositions
TW200711649A (en) 2005-06-17 2007-04-01 Combinatorx Inc Combination therapy for the treatment of immunoinflammatory disorders
JP5101894B2 (ja) * 2007-01-15 2012-12-19 サントリーホールディングス株式会社 高度不飽和脂肪酸及びこれを含有する脂質の製造方法
ITMI20070555A1 (it) 2007-03-21 2007-06-20 Giuliani Spa Composizione provvista di attivita' di inibizione sulla 5 alfa-reduttasi
EP2271223A2 (de) 2008-04-25 2011-01-12 BASF Plant Science GmbH Pflanzensamenöl
GB0907413D0 (en) 2009-04-29 2009-06-10 Equateq Ltd Novel methods
CA2690488C (en) * 2010-01-19 2013-06-11 Accucaps Industries Limited Pharmaceutical formulations of naproxen for soft gel encapsulation and combinations thereof
GB201001345D0 (en) 2010-01-27 2010-03-17 Equateq Ltd Process for preparing and purifying fatty acids
AU2011349718B2 (en) 2010-12-21 2017-02-09 Nestec S.A. Methods and compositions for preventing and treating osteoarthritis
RU2014119948A (ru) 2011-10-19 2015-11-27 Дигнити Сайенсиз Лимитед ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ DGLA И/ИЛИ 15-HETrE, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
US8293790B2 (en) 2011-10-19 2012-10-23 Dignity Sciences Limited Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof
CA2856715A1 (en) 2011-11-29 2013-06-06 Dignity Sciences Limited Compositions comprising 20-carbon fatty acids and methods of making and using same
CN107050457A (zh) * 2012-01-06 2017-08-18 翁特拉制药公司 游离酸形式的ω‑3多不饱和脂肪酸的富含dpa组合物
US20120264705A1 (en) 2012-01-26 2012-10-18 Dignity Sciences Limited Antimicrobial compositions comprising 15-hetre and methods of use thereof
US20130267598A1 (en) 2012-02-23 2013-10-10 Dignity Sciences Limited Pharmaceutical compositions comprising dgla, 15-ohepa, and/or 15-hetre and methods of reducing sebum production using same
EP2833740B1 (en) * 2012-04-04 2016-09-14 Pronova BioPharma Norge AS Compositions comprising omega-3 fatty acids and vitamin d for acne vulgaris and/or eczema, and methods and uses thereof
GB2504061A (en) * 2012-05-25 2014-01-22 Dignity Sciences Ltd Omega-6 Enriched PUFA Phospholipids
WO2014022816A2 (en) 2012-08-03 2014-02-06 Dignity Sciences Limited Pharmaceutical compositions comprising 15-hetre and methods of treating or preventing arthritis using same
GB201216385D0 (en) 2012-09-13 2012-10-31 Chrysalis Pharma Ag A pharmaceutical composition
MX375328B (es) * 2014-06-04 2025-03-06 Ds Biopharma Ltd Composiciones farmacéuticas que comprenden ácido dihomo-gamma-linolénico (dgla) y uso de las mismas
US10047033B2 (en) 2015-05-13 2018-08-14 Ds Biopharma Limited Compositions comprising oxo-derivatives of fatty acids and methods of making and using same
CN108778266A (zh) 2016-01-07 2018-11-09 Ds生物制药有限公司 包含二高γ亚麻酸（DGLA）的医药组合物和其用途

Similar Documents

Publication Publication Date Title
JP4415243B2 (ja) 脂肪酸の治療効果の増強作用
JP6682596B2 (ja) ω３脂肪酸の自己乳化組成物
CN100423718C (zh) 治疗精神性和神经性疾病的高纯乙基epa及其他epa衍生物
US6630157B1 (en) Therapeutic and dietary compositions containing essential fatty acids and bioactive disulphides
RU2020101477A (ru) Фармацевтические композиции, содержащие дглк, и их применение
ES2826201T3 (es) Cápsulas entéricas blandas que comprenden ácidos grasos poliinsaturados
JP7132907B2 (ja) ニコチンアミドリボシド及びプテロスチルベン組成物及び神経変性障害の治療方法
JP2004531568A (ja) 補酵素ｑおよびエイコサペンタエン酸（ｅｐａ）
JP2008540394A5 (enExample)
GB2223943A (en) Oral disage forms of omega-3 polyunsaturated acids
JP2014193924A (ja) オメガ３脂肪酸製剤
JP6313765B2 (ja) 医薬組成物
CZ301307B6 (cs) Použití esenciálních mastných kyselin pro prevenci kardiovaskulárních príhod
JPH11209279A (ja) 体重減少および肥満処置の方法
JP2012513774A (ja) ニトロ脂肪酸を含有する栄養補助物
JP2015503590A5 (enExample)
EP0734723A1 (en) Therapeutic composition for hyperparathyroidism of patient subjected to artificial dialysis
JP2006503031A5 (enExample)
CN117204564B (zh) 一种高生物利用度的水溶性辅酶q10复合载体、制备方法及其应用
CN101757624B (zh) 一种预防和治疗老年痴呆症的组合物
US9314435B2 (en) Stable formulations of antiplatelet agents, omega-3 fatty acids and amylose in soft gelatin capsules
GB2504061A (en) Omega-6 Enriched PUFA Phospholipids
RU2150269C1 (ru) Мягкая капсула с лактобактериями для лечения дисбактериозов влагалища
Aucamp et al. Pilot trial to determine the efficacy of a low dose of fish oil in the treatment of angina pectoris in the geriatric patient
JPS6121065A (ja) 栄養補助食品